There is evidence that the earliest signs of tau pathology emerge in the brainstem [27, 28] and as AD-PRS has been linked to tau biomarkers [33], we speculate that alterations in brainstem volume may represent a candidate biomarker for individuals with high genetic risk for AD. This evidence concerns the gene MAPT and Alzheimer disease.